Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

		00540
Vashington,	D.C.	20549

STAT	EME	ENT	OF	С

CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* STARKS DANIEL J				2. Issuer Name and Ticker or Trading Symbol ABBOTT LABORATORIES [ABT]								5. Relationship of Repo (Check all applicable) X Director			10%	5 Owner		
(Last) 100 ABE	(Fir BOTT PARI	,	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 10/27/2022							Officer (give title below) Other (specify below)						
(Street) ABBOT	Γ IL	6	50064	4. If Amendment, Date of					ate of Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(Sta		Zip)															
Table I - Non-Derivat 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date,		3. Transaction Code (Instr.		, Disposed of, or Benef 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and) or	5. Amount of Securities Beneficially Owned Following				7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	v	Amo		(A) or (D)	Pric	ce	Transa	Reported Fransaction(s) Instr. 3 and 4)			
Common shares without par value 10/27/2022					S		40	,687	D	\$97.303		6,882,813			D			
Common	shares with	out par value	10/27/2022	/2022					9,	313	D	\$9	98.136 ⁽²⁾	6,873,500			D	
Common shares without par value												258(3)			I	Alynne Starks 2012 Irrevocable Trust		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any				5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ative rities ired osed	Expiration Date (Month/Day/Year)		A S U D	7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		Derivative Security (Instr. 5) Bene Own		owing (I) (Inst orted isaction(s)		Beneficial Ownership ect (Instr. 4)		
				Code	v	(A)	(D)	Date Exercis	sable	Expirati Date			Amount or Number of Shares					

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$96.82 to \$97.80, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$97.82 to \$98.67, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 3. Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

/s/ Daniel J. Starks by Jessica 10/31/2022 H. Paik, Attorney-in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.